Hi Doc,
This study found that Remestemcel-L lead to significantly better treatment and safety outcomes in the most severe grades of aGVHD (grades III-IV/C-D). Overall, across all grades Remestemcel-L was found to have an improved treatment outcome but it was not statistically significant (not enough patients for statical significance). However, saftey was significantly better in Remestemcel-L across all treated grades (50%+ improvement).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983491/#!po=45.0000
Figure 2. Risk Ratio for Day 28 ORR of Remestemcel-L-rknd (N=55) Versus Ruxolitinib (N=49)Figure 3. Risk Ratio for 28-day ORR of Remestemcel-L-rknd Versus Ruxolitinib in the Grade III-IV aGVHD Subgroup (N=49 for remestemcel-L-rknd and N=36 for ruxolitinib)
Hi Doc,This study found that Remestemcel-L lead to significantly...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
0.040(3.88%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $4.797M | 4.492M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 42 | 126568 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 9484 | 17 |
View Market Depth
| Last trade - 14.53pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |